Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers

Next Previous
Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivermectin (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacokinetics
  • Sponsors MedinCell S.A.

Most Recent Events

  • 19 Apr 2021 Status changed from recruiting to completed, according to a MedinCell S.A. media release.
  • 19 Apr 2021 Preliminary results presented in a MedinCell S.A. media release.
  • 05 Mar 2021 According to a MedinCell media release, the company is currently completing a clinical trial aiming at demonstrating the safety of ivermectin when taken daily in oral form in order to simulate the continuous release of the drug by a long-acting injectable, full results from this study will be made available in the coming weeks which will support the regulatory review of this long-acting injectable formulation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top